nodes	percent_of_prediction	percent_of_DWPC	metapath
Duloxetine—CYP2D6—Lomustine—brain cancer	0.141	0.329	CbGbCtD
Duloxetine—CYP1A2—Carmustine—brain cancer	0.14	0.325	CbGbCtD
Duloxetine—CYP2D6—Hydroxyurea—brain cancer	0.107	0.249	CbGbCtD
Duloxetine—CYP1A2—Etoposide—brain cancer	0.0414	0.0965	CbGbCtD
Duloxetine—HTR2C—choroid plexus—brain cancer	0.0253	0.119	CbGeAlD
Duloxetine—HTR2A—choroid plexus—brain cancer	0.0127	0.0599	CbGeAlD
Duloxetine—HTR6—ganglion—brain cancer	0.00799	0.0377	CbGeAlD
Duloxetine—SLC6A3—telencephalic ventricle—brain cancer	0.00767	0.0362	CbGeAlD
Duloxetine—HTR2C—telencephalic ventricle—brain cancer	0.00742	0.035	CbGeAlD
Duloxetine—HTR2A—trigeminal nerve—brain cancer	0.00642	0.0303	CbGeAlD
Duloxetine—HTR2A—cerebellar cortex—brain cancer	0.0064	0.0301	CbGeAlD
Duloxetine—HTR2A—vein—brain cancer	0.0058	0.0274	CbGeAlD
Duloxetine—SLC6A3—ganglion—brain cancer	0.00478	0.0225	CbGeAlD
Duloxetine—HTR2C—ganglion—brain cancer	0.00462	0.0218	CbGeAlD
Duloxetine—HTR2A—cranial nerve—brain cancer	0.00458	0.0216	CbGeAlD
Duloxetine—HTR2A—pons—brain cancer	0.00452	0.0213	CbGeAlD
Duloxetine—NPY1R—telencephalon—brain cancer	0.00438	0.0206	CbGeAlD
Duloxetine—SLC6A4—ganglion—brain cancer	0.00438	0.0206	CbGeAlD
Duloxetine—SLC6A2—ganglion—brain cancer	0.00385	0.0182	CbGeAlD
Duloxetine—HTR2A—telencephalic ventricle—brain cancer	0.00372	0.0175	CbGeAlD
Duloxetine—NPY1R—gonad—brain cancer	0.00365	0.0172	CbGeAlD
Duloxetine—SLC6A3—hindbrain—brain cancer	0.00362	0.0171	CbGeAlD
Duloxetine—NPY1R—pituitary gland—brain cancer	0.00357	0.0168	CbGeAlD
Duloxetine—SLC6A4—hindbrain—brain cancer	0.00332	0.0156	CbGeAlD
Duloxetine—HTR2A—pineal body—brain cancer	0.00323	0.0152	CbGeAlD
Duloxetine—HTR6—telencephalon—brain cancer	0.00308	0.0145	CbGeAlD
Duloxetine—NPY1R—endocrine gland—brain cancer	0.00276	0.013	CbGeAlD
Duloxetine—NPY1R—head—brain cancer	0.00273	0.0129	CbGeAlD
Duloxetine—NPY1R—central nervous system—brain cancer	0.00249	0.0117	CbGeAlD
Duloxetine—HTR2A—ganglion—brain cancer	0.00232	0.0109	CbGeAlD
Duloxetine—SLC6A3—brainstem—brain cancer	0.00208	0.00979	CbGeAlD
Duloxetine—HTR2C—brainstem—brain cancer	0.00201	0.00946	CbGeAlD
Duloxetine—HTR2A—endothelium—brain cancer	0.002	0.00941	CbGeAlD
Duloxetine—NPY1R—brain—brain cancer	0.00198	0.00931	CbGeAlD
Duloxetine—HTR6—head—brain cancer	0.00192	0.00905	CbGeAlD
Duloxetine—SLC6A4—brainstem—brain cancer	0.0019	0.00897	CbGeAlD
Duloxetine—SLC6A3—telencephalon—brain cancer	0.00184	0.00868	CbGeAlD
Duloxetine—HTR2A—blood vessel—brain cancer	0.00184	0.00868	CbGeAlD
Duloxetine—HTR2C—telencephalon—brain cancer	0.00178	0.00839	CbGeAlD
Duloxetine—HTR2A—hindbrain—brain cancer	0.00176	0.00828	CbGeAlD
Duloxetine—HTR6—central nervous system—brain cancer	0.00175	0.00826	CbGeAlD
Duloxetine—SLC6A4—telencephalon—brain cancer	0.00169	0.00796	CbGeAlD
Duloxetine—SLC6A2—brainstem—brain cancer	0.00168	0.00789	CbGeAlD
Duloxetine—CYP2D6—hindbrain—brain cancer	0.0016	0.00754	CbGeAlD
Duloxetine—SLC6A2—telencephalon—brain cancer	0.00149	0.00701	CbGeAlD
Duloxetine—HTR2C—medulla oblongata—brain cancer	0.0014	0.0066	CbGeAlD
Duloxetine—HTR6—brain—brain cancer	0.00139	0.00656	CbGeAlD
Duloxetine—SLC6A3—midbrain—brain cancer	0.00132	0.00624	CbGeAlD
Duloxetine—SLC6A3—spinal cord—brain cancer	0.00129	0.00608	CbGeAlD
Duloxetine—HTR2C—midbrain—brain cancer	0.00128	0.00603	CbGeAlD
Duloxetine—HTR2C—spinal cord—brain cancer	0.00125	0.00588	CbGeAlD
Duloxetine—SLC6A2—gonad—brain cancer	0.00124	0.00585	CbGeAlD
Duloxetine—SLC6A4—midbrain—brain cancer	0.00121	0.00572	CbGeAlD
Duloxetine—SLC6A4—spinal cord—brain cancer	0.00118	0.00558	CbGeAlD
Duloxetine—SLC6A2—medulla oblongata—brain cancer	0.00117	0.00551	CbGeAlD
Duloxetine—SLC6A3—head—brain cancer	0.00115	0.00541	CbGeAlD
Duloxetine—HTR2C—head—brain cancer	0.00111	0.00523	CbGeAlD
Duloxetine—SLC6A4—endocrine gland—brain cancer	0.00107	0.00502	CbGeAlD
Duloxetine—SLC6A4—head—brain cancer	0.00105	0.00496	CbGeAlD
Duloxetine—SLC6A3—central nervous system—brain cancer	0.00105	0.00494	CbGeAlD
Duloxetine—SLC6A3—cerebellum—brain cancer	0.00102	0.00482	CbGeAlD
Duloxetine—HTR2C—central nervous system—brain cancer	0.00101	0.00477	CbGeAlD
Duloxetine—HTR2A—brainstem—brain cancer	0.00101	0.00475	CbGeAlD
Duloxetine—SLC6A4—central nervous system—brain cancer	0.00096	0.00452	CbGeAlD
Duloxetine—SLC6A2—endocrine gland—brain cancer	0.000938	0.00442	CbGeAlD
Duloxetine—SLC6A2—head—brain cancer	0.000926	0.00436	CbGeAlD
Duloxetine—CYP2D6—brainstem—brain cancer	0.000917	0.00432	CbGeAlD
Duloxetine—HTR2A—telencephalon—brain cancer	0.000893	0.00421	CbGeAlD
Duloxetine—SLC6A2—central nervous system—brain cancer	0.000845	0.00398	CbGeAlD
Duloxetine—SLC6A3—brain—brain cancer	0.000831	0.00392	CbGeAlD
Duloxetine—CYP2D6—telencephalon—brain cancer	0.000814	0.00384	CbGeAlD
Duloxetine—HTR2C—brain—brain cancer	0.000804	0.00379	CbGeAlD
Duloxetine—SLC6A4—brain—brain cancer	0.000762	0.00359	CbGeAlD
Duloxetine—HTR2A—gonad—brain cancer	0.000746	0.00351	CbGeAlD
Duloxetine—HTR2A—pituitary gland—brain cancer	0.000727	0.00343	CbGeAlD
Duloxetine—CYP1A2—endocrine gland—brain cancer	0.000721	0.0034	CbGeAlD
Duloxetine—HTR2A—medulla oblongata—brain cancer	0.000702	0.00331	CbGeAlD
Duloxetine—SLC6A2—brain—brain cancer	0.000671	0.00316	CbGeAlD
Duloxetine—HTR2A—midbrain—brain cancer	0.000642	0.00302	CbGeAlD
Duloxetine—HTR2A—spinal cord—brain cancer	0.000626	0.00295	CbGeAlD
Duloxetine—Fluoxetine—CYP2C9—brain cancer	0.000613	1	CrCbGaD
Duloxetine—Haemoglobin—Carmustine—brain cancer	0.000603	0.00191	CcSEcCtD
Duloxetine—Haemorrhage—Carmustine—brain cancer	0.0006	0.0019	CcSEcCtD
Duloxetine—Ill-defined disorder—Hydroxyurea—brain cancer	0.000599	0.0019	CcSEcCtD
Duloxetine—Anaemia—Hydroxyurea—brain cancer	0.000597	0.00189	CcSEcCtD
Duloxetine—Hallucination—Carmustine—brain cancer	0.000597	0.00189	CcSEcCtD
Duloxetine—Hypoaesthesia—Carmustine—brain cancer	0.000597	0.00189	CcSEcCtD
Duloxetine—Decreased appetite—Procarbazine—brain cancer	0.000592	0.00188	CcSEcCtD
Duloxetine—Alanine aminotransferase increased—Etoposide—brain cancer	0.000591	0.00188	CcSEcCtD
Duloxetine—Oedema peripheral—Carmustine—brain cancer	0.000591	0.00187	CcSEcCtD
Duloxetine—Connective tissue disorder—Carmustine—brain cancer	0.000589	0.00187	CcSEcCtD
Duloxetine—Fatigue—Procarbazine—brain cancer	0.000587	0.00186	CcSEcCtD
Duloxetine—Haemoglobin—Temozolomide—brain cancer	0.000582	0.00185	CcSEcCtD
Duloxetine—Malaise—Hydroxyurea—brain cancer	0.000582	0.00185	CcSEcCtD
Duloxetine—Pain—Procarbazine—brain cancer	0.000582	0.00185	CcSEcCtD
Duloxetine—Constipation—Procarbazine—brain cancer	0.000582	0.00185	CcSEcCtD
Duloxetine—Haemorrhage—Temozolomide—brain cancer	0.00058	0.00184	CcSEcCtD
Duloxetine—Hepatitis—Temozolomide—brain cancer	0.00058	0.00184	CcSEcCtD
Duloxetine—Dysphagia—Etoposide—brain cancer	0.000579	0.00184	CcSEcCtD
Duloxetine—Leukopenia—Hydroxyurea—brain cancer	0.000578	0.00183	CcSEcCtD
Duloxetine—Visual impairment—Carmustine—brain cancer	0.000578	0.00183	CcSEcCtD
Duloxetine—Hypoaesthesia—Temozolomide—brain cancer	0.000577	0.00183	CcSEcCtD
Duloxetine—Hallucination—Temozolomide—brain cancer	0.000577	0.00183	CcSEcCtD
Duloxetine—Pharyngitis—Temozolomide—brain cancer	0.000575	0.00182	CcSEcCtD
Duloxetine—Urinary tract disorder—Temozolomide—brain cancer	0.000572	0.00182	CcSEcCtD
Duloxetine—Oedema peripheral—Temozolomide—brain cancer	0.000571	0.00181	CcSEcCtD
Duloxetine—Connective tissue disorder—Temozolomide—brain cancer	0.000569	0.00181	CcSEcCtD
Duloxetine—Urethral disorder—Temozolomide—brain cancer	0.000568	0.0018	CcSEcCtD
Duloxetine—Sweating increased—Etoposide—brain cancer	0.000564	0.00179	CcSEcCtD
Duloxetine—HTR2A—endocrine gland—brain cancer	0.000564	0.00266	CbGeAlD
Duloxetine—Feeling abnormal—Procarbazine—brain cancer	0.000561	0.00178	CcSEcCtD
Duloxetine—Eye disorder—Carmustine—brain cancer	0.00056	0.00178	CcSEcCtD
Duloxetine—Convulsion—Hydroxyurea—brain cancer	0.000559	0.00178	CcSEcCtD
Duloxetine—Visual impairment—Temozolomide—brain cancer	0.000558	0.00177	CcSEcCtD
Duloxetine—Gastrointestinal pain—Procarbazine—brain cancer	0.000557	0.00177	CcSEcCtD
Duloxetine—Flushing—Carmustine—brain cancer	0.000557	0.00177	CcSEcCtD
Duloxetine—HTR2A—head—brain cancer	0.000556	0.00262	CbGeAlD
Duloxetine—Erythema multiforme—Temozolomide—brain cancer	0.000548	0.00174	CcSEcCtD
Duloxetine—Unspecified disorder of skin and subcutaneous tissue—Hydroxyurea—brain cancer	0.000546	0.00173	CcSEcCtD
Duloxetine—Discomfort—Hydroxyurea—brain cancer	0.000543	0.00172	CcSEcCtD
Duloxetine—Eye disorder—Temozolomide—brain cancer	0.000542	0.00172	CcSEcCtD
Duloxetine—Urticaria—Procarbazine—brain cancer	0.000541	0.00172	CcSEcCtD
Duloxetine—Tinnitus—Temozolomide—brain cancer	0.00054	0.00171	CcSEcCtD
Duloxetine—Abdominal pain—Procarbazine—brain cancer	0.000538	0.00171	CcSEcCtD
Duloxetine—Body temperature increased—Procarbazine—brain cancer	0.000538	0.00171	CcSEcCtD
Duloxetine—Flushing—Temozolomide—brain cancer	0.000538	0.00171	CcSEcCtD
Duloxetine—Cardiac disorder—Temozolomide—brain cancer	0.000538	0.00171	CcSEcCtD
Duloxetine—Arrhythmia—Carmustine—brain cancer	0.000536	0.0017	CcSEcCtD
Duloxetine—Alopecia—Carmustine—brain cancer	0.00053	0.00168	CcSEcCtD
Duloxetine—Oedema—Hydroxyurea—brain cancer	0.000527	0.00167	CcSEcCtD
Duloxetine—Angiopathy—Temozolomide—brain cancer	0.000526	0.00167	CcSEcCtD
Duloxetine—Mental disorder—Carmustine—brain cancer	0.000525	0.00167	CcSEcCtD
Duloxetine—Infection—Hydroxyurea—brain cancer	0.000524	0.00166	CcSEcCtD
Duloxetine—Immune system disorder—Temozolomide—brain cancer	0.000523	0.00166	CcSEcCtD
Duloxetine—Mediastinal disorder—Temozolomide—brain cancer	0.000522	0.00166	CcSEcCtD
Duloxetine—Erythema—Carmustine—brain cancer	0.000522	0.00166	CcSEcCtD
Duloxetine—Malnutrition—Carmustine—brain cancer	0.000522	0.00166	CcSEcCtD
Duloxetine—Chills—Temozolomide—brain cancer	0.00052	0.00165	CcSEcCtD
Duloxetine—Nervous system disorder—Hydroxyurea—brain cancer	0.000517	0.00164	CcSEcCtD
Duloxetine—Infestation—Etoposide—brain cancer	0.000517	0.00164	CcSEcCtD
Duloxetine—Infestation NOS—Etoposide—brain cancer	0.000517	0.00164	CcSEcCtD
Duloxetine—Thrombocytopenia—Hydroxyurea—brain cancer	0.000516	0.00164	CcSEcCtD
Duloxetine—CYP2D6—endocrine gland—brain cancer	0.000513	0.00242	CbGeAlD
Duloxetine—Stevens-Johnson syndrome—Etoposide—brain cancer	0.000512	0.00162	CcSEcCtD
Duloxetine—Alopecia—Temozolomide—brain cancer	0.000512	0.00162	CcSEcCtD
Duloxetine—Skin disorder—Hydroxyurea—brain cancer	0.000512	0.00162	CcSEcCtD
Duloxetine—Acute coronary syndrome—Etoposide—brain cancer	0.000509	0.00162	CcSEcCtD
Duloxetine—HTR2A—central nervous system—brain cancer	0.000508	0.00239	CbGeAlD
Duloxetine—Renal failure—Etoposide—brain cancer	0.000508	0.00161	CcSEcCtD
Duloxetine—Mental disorder—Temozolomide—brain cancer	0.000508	0.00161	CcSEcCtD
Duloxetine—CYP2D6—head—brain cancer	0.000507	0.00239	CbGeAlD
Duloxetine—Myocardial infarction—Etoposide—brain cancer	0.000506	0.00161	CcSEcCtD
Duloxetine—Back pain—Carmustine—brain cancer	0.000505	0.0016	CcSEcCtD
Duloxetine—Erythema—Temozolomide—brain cancer	0.000504	0.0016	CcSEcCtD
Duloxetine—Malnutrition—Temozolomide—brain cancer	0.000504	0.0016	CcSEcCtD
Duloxetine—Stomatitis—Etoposide—brain cancer	0.000504	0.0016	CcSEcCtD
Duloxetine—Jaundice—Etoposide—brain cancer	0.000504	0.0016	CcSEcCtD
Duloxetine—Anorexia—Hydroxyurea—brain cancer	0.000502	0.00159	CcSEcCtD
Duloxetine—Hypersensitivity—Procarbazine—brain cancer	0.000502	0.00159	CcSEcCtD
Duloxetine—HTR2A—cerebellum—brain cancer	0.000496	0.00234	CbGeAlD
Duloxetine—Dysgeusia—Temozolomide—brain cancer	0.000494	0.00157	CcSEcCtD
Duloxetine—Vision blurred—Carmustine—brain cancer	0.000492	0.00156	CcSEcCtD
Duloxetine—Tremor—Carmustine—brain cancer	0.000489	0.00155	CcSEcCtD
Duloxetine—Asthenia—Procarbazine—brain cancer	0.000489	0.00155	CcSEcCtD
Duloxetine—Hepatobiliary disease—Etoposide—brain cancer	0.000489	0.00155	CcSEcCtD
Duloxetine—Back pain—Temozolomide—brain cancer	0.000488	0.00155	CcSEcCtD
Duloxetine—Anaemia—Carmustine—brain cancer	0.000482	0.00153	CcSEcCtD
Duloxetine—Pruritus—Procarbazine—brain cancer	0.000482	0.00153	CcSEcCtD
Duloxetine—Agitation—Carmustine—brain cancer	0.00048	0.00152	CcSEcCtD
Duloxetine—Vision blurred—Temozolomide—brain cancer	0.000475	0.00151	CcSEcCtD
Duloxetine—Tremor—Temozolomide—brain cancer	0.000473	0.0015	CcSEcCtD
Duloxetine—Somnolence—Hydroxyurea—brain cancer	0.000469	0.00149	CcSEcCtD
Duloxetine—Ill-defined disorder—Temozolomide—brain cancer	0.000468	0.00149	CcSEcCtD
Duloxetine—Leukopenia—Carmustine—brain cancer	0.000467	0.00148	CcSEcCtD
Duloxetine—Anaemia—Temozolomide—brain cancer	0.000466	0.00148	CcSEcCtD
Duloxetine—Diarrhoea—Procarbazine—brain cancer	0.000466	0.00148	CcSEcCtD
Duloxetine—Dyspepsia—Hydroxyurea—brain cancer	0.000464	0.00147	CcSEcCtD
Duloxetine—Agitation—Temozolomide—brain cancer	0.000464	0.00147	CcSEcCtD
Duloxetine—CYP2D6—central nervous system—brain cancer	0.000463	0.00218	CbGeAlD
Duloxetine—Hypoaesthesia—Etoposide—brain cancer	0.000461	0.00146	CcSEcCtD
Duloxetine—Angioedema—Temozolomide—brain cancer	0.000461	0.00146	CcSEcCtD
Duloxetine—Decreased appetite—Hydroxyurea—brain cancer	0.000458	0.00145	CcSEcCtD
Duloxetine—Urinary tract disorder—Etoposide—brain cancer	0.000458	0.00145	CcSEcCtD
Duloxetine—Gastrointestinal disorder—Hydroxyurea—brain cancer	0.000455	0.00144	CcSEcCtD
Duloxetine—Malaise—Temozolomide—brain cancer	0.000455	0.00144	CcSEcCtD
Duloxetine—Urethral disorder—Etoposide—brain cancer	0.000455	0.00144	CcSEcCtD
Duloxetine—Fatigue—Hydroxyurea—brain cancer	0.000454	0.00144	CcSEcCtD
Duloxetine—Vertigo—Temozolomide—brain cancer	0.000453	0.00144	CcSEcCtD
Duloxetine—Convulsion—Carmustine—brain cancer	0.000452	0.00144	CcSEcCtD
Duloxetine—CYP2D6—cerebellum—brain cancer	0.000452	0.00213	CbGeAlD
Duloxetine—Leukopenia—Temozolomide—brain cancer	0.000452	0.00143	CcSEcCtD
Duloxetine—Hypertension—Carmustine—brain cancer	0.000451	0.00143	CcSEcCtD
Duloxetine—Pain—Hydroxyurea—brain cancer	0.000451	0.00143	CcSEcCtD
Duloxetine—Constipation—Hydroxyurea—brain cancer	0.000451	0.00143	CcSEcCtD
Duloxetine—Dizziness—Procarbazine—brain cancer	0.00045	0.00143	CcSEcCtD
Duloxetine—Palpitations—Temozolomide—brain cancer	0.000446	0.00141	CcSEcCtD
Duloxetine—Chest pain—Carmustine—brain cancer	0.000444	0.00141	CcSEcCtD
Duloxetine—Myalgia—Carmustine—brain cancer	0.000444	0.00141	CcSEcCtD
Duloxetine—Anxiety—Carmustine—brain cancer	0.000443	0.00141	CcSEcCtD
Duloxetine—Cough—Temozolomide—brain cancer	0.00044	0.0014	CcSEcCtD
Duloxetine—Erythema multiforme—Etoposide—brain cancer	0.000438	0.00139	CcSEcCtD
Duloxetine—Convulsion—Temozolomide—brain cancer	0.000437	0.00139	CcSEcCtD
Duloxetine—Hypertension—Temozolomide—brain cancer	0.000436	0.00138	CcSEcCtD
Duloxetine—Feeling abnormal—Hydroxyurea—brain cancer	0.000434	0.00138	CcSEcCtD
Duloxetine—Eye disorder—Etoposide—brain cancer	0.000433	0.00137	CcSEcCtD
Duloxetine—Vomiting—Procarbazine—brain cancer	0.000433	0.00137	CcSEcCtD
Duloxetine—Flushing—Etoposide—brain cancer	0.00043	0.00137	CcSEcCtD
Duloxetine—Cardiac disorder—Etoposide—brain cancer	0.00043	0.00137	CcSEcCtD
Duloxetine—Confusional state—Carmustine—brain cancer	0.00043	0.00136	CcSEcCtD
Duloxetine—Arthralgia—Temozolomide—brain cancer	0.000429	0.00136	CcSEcCtD
Duloxetine—Myalgia—Temozolomide—brain cancer	0.000429	0.00136	CcSEcCtD
Duloxetine—Rash—Procarbazine—brain cancer	0.000429	0.00136	CcSEcCtD
Duloxetine—Dermatitis—Procarbazine—brain cancer	0.000429	0.00136	CcSEcCtD
Duloxetine—Anxiety—Temozolomide—brain cancer	0.000428	0.00136	CcSEcCtD
Duloxetine—Headache—Procarbazine—brain cancer	0.000427	0.00135	CcSEcCtD
Duloxetine—Unspecified disorder of skin and subcutaneous tissue—Temozolomide—brain cancer	0.000427	0.00135	CcSEcCtD
Duloxetine—Oedema—Carmustine—brain cancer	0.000426	0.00135	CcSEcCtD
Duloxetine—Discomfort—Temozolomide—brain cancer	0.000424	0.00135	CcSEcCtD
Duloxetine—Infection—Carmustine—brain cancer	0.000423	0.00134	CcSEcCtD
Duloxetine—Angiopathy—Etoposide—brain cancer	0.000421	0.00133	CcSEcCtD
Duloxetine—Dry mouth—Temozolomide—brain cancer	0.00042	0.00133	CcSEcCtD
Duloxetine—Immune system disorder—Etoposide—brain cancer	0.000419	0.00133	CcSEcCtD
Duloxetine—Mediastinal disorder—Etoposide—brain cancer	0.000418	0.00133	CcSEcCtD
Duloxetine—Thrombocytopenia—Carmustine—brain cancer	0.000417	0.00132	CcSEcCtD
Duloxetine—Body temperature increased—Hydroxyurea—brain cancer	0.000417	0.00132	CcSEcCtD
Duloxetine—Chills—Etoposide—brain cancer	0.000416	0.00132	CcSEcCtD
Duloxetine—Tachycardia—Carmustine—brain cancer	0.000416	0.00132	CcSEcCtD
Duloxetine—Confusional state—Temozolomide—brain cancer	0.000415	0.00132	CcSEcCtD
Duloxetine—Oedema—Temozolomide—brain cancer	0.000412	0.00131	CcSEcCtD
Duloxetine—Anaphylactic shock—Temozolomide—brain cancer	0.000412	0.00131	CcSEcCtD
Duloxetine—Alopecia—Etoposide—brain cancer	0.00041	0.0013	CcSEcCtD
Duloxetine—Infection—Temozolomide—brain cancer	0.000409	0.0013	CcSEcCtD
Duloxetine—Anorexia—Carmustine—brain cancer	0.000406	0.00129	CcSEcCtD
Duloxetine—Nausea—Procarbazine—brain cancer	0.000404	0.00128	CcSEcCtD
Duloxetine—Nervous system disorder—Temozolomide—brain cancer	0.000404	0.00128	CcSEcCtD
Duloxetine—HTR2A—brain—brain cancer	0.000403	0.0019	CbGeAlD
Duloxetine—Thrombocytopenia—Temozolomide—brain cancer	0.000403	0.00128	CcSEcCtD
Duloxetine—Skin disorder—Temozolomide—brain cancer	0.0004	0.00127	CcSEcCtD
Duloxetine—Hyperhidrosis—Temozolomide—brain cancer	0.000398	0.00126	CcSEcCtD
Duloxetine—Dysgeusia—Etoposide—brain cancer	0.000395	0.00125	CcSEcCtD
Duloxetine—Anorexia—Temozolomide—brain cancer	0.000392	0.00125	CcSEcCtD
Duloxetine—Back pain—Etoposide—brain cancer	0.00039	0.00124	CcSEcCtD
Duloxetine—Hypersensitivity—Hydroxyurea—brain cancer	0.000388	0.00123	CcSEcCtD
Duloxetine—Musculoskeletal discomfort—Carmustine—brain cancer	0.000388	0.00123	CcSEcCtD
Duloxetine—Muscle spasms—Etoposide—brain cancer	0.000388	0.00123	CcSEcCtD
Duloxetine—Insomnia—Carmustine—brain cancer	0.000385	0.00122	CcSEcCtD
Duloxetine—Paraesthesia—Carmustine—brain cancer	0.000383	0.00121	CcSEcCtD
Duloxetine—Somnolence—Carmustine—brain cancer	0.000379	0.0012	CcSEcCtD
Duloxetine—Asthenia—Hydroxyurea—brain cancer	0.000378	0.0012	CcSEcCtD
Duloxetine—Musculoskeletal discomfort—Temozolomide—brain cancer	0.000375	0.00119	CcSEcCtD
Duloxetine—Ill-defined disorder—Etoposide—brain cancer	0.000375	0.00119	CcSEcCtD
Duloxetine—Anaemia—Etoposide—brain cancer	0.000373	0.00118	CcSEcCtD
Duloxetine—Insomnia—Temozolomide—brain cancer	0.000372	0.00118	CcSEcCtD
Duloxetine—Decreased appetite—Carmustine—brain cancer	0.00037	0.00118	CcSEcCtD
Duloxetine—Paraesthesia—Temozolomide—brain cancer	0.00037	0.00117	CcSEcCtD
Duloxetine—Gastrointestinal disorder—Carmustine—brain cancer	0.000368	0.00117	CcSEcCtD
Duloxetine—CYP2D6—brain—brain cancer	0.000367	0.00173	CbGeAlD
Duloxetine—Somnolence—Temozolomide—brain cancer	0.000366	0.00116	CcSEcCtD
Duloxetine—Pain—Carmustine—brain cancer	0.000364	0.00116	CcSEcCtD
Duloxetine—Constipation—Carmustine—brain cancer	0.000364	0.00116	CcSEcCtD
Duloxetine—Malaise—Etoposide—brain cancer	0.000364	0.00116	CcSEcCtD
Duloxetine—Vertigo—Etoposide—brain cancer	0.000363	0.00115	CcSEcCtD
Duloxetine—Dyspepsia—Temozolomide—brain cancer	0.000362	0.00115	CcSEcCtD
Duloxetine—Leukopenia—Etoposide—brain cancer	0.000361	0.00115	CcSEcCtD
Duloxetine—Diarrhoea—Hydroxyurea—brain cancer	0.000361	0.00114	CcSEcCtD
Duloxetine—Decreased appetite—Temozolomide—brain cancer	0.000358	0.00114	CcSEcCtD
Duloxetine—Gastrointestinal disorder—Temozolomide—brain cancer	0.000355	0.00113	CcSEcCtD
Duloxetine—Fatigue—Temozolomide—brain cancer	0.000355	0.00113	CcSEcCtD
Duloxetine—Loss of consciousness—Etoposide—brain cancer	0.000355	0.00113	CcSEcCtD
Duloxetine—Cough—Etoposide—brain cancer	0.000352	0.00112	CcSEcCtD
Duloxetine—Constipation—Temozolomide—brain cancer	0.000352	0.00112	CcSEcCtD
Duloxetine—Pain—Temozolomide—brain cancer	0.000352	0.00112	CcSEcCtD
Duloxetine—Feeling abnormal—Carmustine—brain cancer	0.000351	0.00111	CcSEcCtD
Duloxetine—Convulsion—Etoposide—brain cancer	0.00035	0.00111	CcSEcCtD
Duloxetine—Hypertension—Etoposide—brain cancer	0.000349	0.00111	CcSEcCtD
Duloxetine—Dizziness—Hydroxyurea—brain cancer	0.000349	0.00111	CcSEcCtD
Duloxetine—Gastrointestinal pain—Carmustine—brain cancer	0.000348	0.00111	CcSEcCtD
Duloxetine—Chest pain—Etoposide—brain cancer	0.000344	0.00109	CcSEcCtD
Duloxetine—Unspecified disorder of skin and subcutaneous tissue—Etoposide—brain cancer	0.000341	0.00108	CcSEcCtD
Duloxetine—Discomfort—Etoposide—brain cancer	0.00034	0.00108	CcSEcCtD
Duloxetine—Feeling abnormal—Temozolomide—brain cancer	0.000339	0.00108	CcSEcCtD
Duloxetine—Abdominal pain—Carmustine—brain cancer	0.000337	0.00107	CcSEcCtD
Duloxetine—Body temperature increased—Carmustine—brain cancer	0.000337	0.00107	CcSEcCtD
Duloxetine—Gastrointestinal pain—Temozolomide—brain cancer	0.000337	0.00107	CcSEcCtD
Duloxetine—Vomiting—Hydroxyurea—brain cancer	0.000335	0.00106	CcSEcCtD
Duloxetine—Rash—Hydroxyurea—brain cancer	0.000332	0.00105	CcSEcCtD
Duloxetine—Confusional state—Etoposide—brain cancer	0.000332	0.00105	CcSEcCtD
Duloxetine—Dermatitis—Hydroxyurea—brain cancer	0.000332	0.00105	CcSEcCtD
Duloxetine—Headache—Hydroxyurea—brain cancer	0.00033	0.00105	CcSEcCtD
Duloxetine—Anaphylactic shock—Etoposide—brain cancer	0.000329	0.00105	CcSEcCtD
Duloxetine—Infection—Etoposide—brain cancer	0.000327	0.00104	CcSEcCtD
Duloxetine—Urticaria—Temozolomide—brain cancer	0.000327	0.00104	CcSEcCtD
Duloxetine—Body temperature increased—Temozolomide—brain cancer	0.000325	0.00103	CcSEcCtD
Duloxetine—Abdominal pain—Temozolomide—brain cancer	0.000325	0.00103	CcSEcCtD
Duloxetine—Thrombocytopenia—Etoposide—brain cancer	0.000323	0.00102	CcSEcCtD
Duloxetine—Tachycardia—Etoposide—brain cancer	0.000322	0.00102	CcSEcCtD
Duloxetine—Skin disorder—Etoposide—brain cancer	0.00032	0.00102	CcSEcCtD
Duloxetine—Hyperhidrosis—Etoposide—brain cancer	0.000318	0.00101	CcSEcCtD
Duloxetine—Anorexia—Etoposide—brain cancer	0.000314	0.000996	CcSEcCtD
Duloxetine—Hypersensitivity—Carmustine—brain cancer	0.000314	0.000996	CcSEcCtD
Duloxetine—Nausea—Hydroxyurea—brain cancer	0.000313	0.000993	CcSEcCtD
Duloxetine—Asthenia—Carmustine—brain cancer	0.000306	0.00097	CcSEcCtD
Duloxetine—Hypersensitivity—Temozolomide—brain cancer	0.000303	0.000962	CcSEcCtD
Duloxetine—Paraesthesia—Etoposide—brain cancer	0.000296	0.000939	CcSEcCtD
Duloxetine—Asthenia—Temozolomide—brain cancer	0.000295	0.000937	CcSEcCtD
Duloxetine—Somnolence—Etoposide—brain cancer	0.000293	0.000929	CcSEcCtD
Duloxetine—Diarrhoea—Carmustine—brain cancer	0.000291	0.000925	CcSEcCtD
Duloxetine—Pruritus—Temozolomide—brain cancer	0.000291	0.000924	CcSEcCtD
Duloxetine—Decreased appetite—Etoposide—brain cancer	0.000286	0.000909	CcSEcCtD
Duloxetine—Gastrointestinal disorder—Etoposide—brain cancer	0.000284	0.000902	CcSEcCtD
Duloxetine—Fatigue—Etoposide—brain cancer	0.000284	0.000901	CcSEcCtD
Duloxetine—Dizziness—Carmustine—brain cancer	0.000282	0.000894	CcSEcCtD
Duloxetine—Constipation—Etoposide—brain cancer	0.000282	0.000894	CcSEcCtD
Duloxetine—Pain—Etoposide—brain cancer	0.000282	0.000894	CcSEcCtD
Duloxetine—Diarrhoea—Temozolomide—brain cancer	0.000282	0.000894	CcSEcCtD
Duloxetine—Dizziness—Temozolomide—brain cancer	0.000272	0.000864	CcSEcCtD
Duloxetine—Feeling abnormal—Etoposide—brain cancer	0.000271	0.000861	CcSEcCtD
Duloxetine—Vomiting—Carmustine—brain cancer	0.000271	0.000859	CcSEcCtD
Duloxetine—Gastrointestinal pain—Etoposide—brain cancer	0.000269	0.000855	CcSEcCtD
Duloxetine—Rash—Carmustine—brain cancer	0.000269	0.000852	CcSEcCtD
Duloxetine—Dermatitis—Carmustine—brain cancer	0.000268	0.000852	CcSEcCtD
Duloxetine—Headache—Carmustine—brain cancer	0.000267	0.000847	CcSEcCtD
Duloxetine—Vomiting—Temozolomide—brain cancer	0.000262	0.000831	CcSEcCtD
Duloxetine—Urticaria—Etoposide—brain cancer	0.000262	0.00083	CcSEcCtD
Duloxetine—Abdominal pain—Etoposide—brain cancer	0.00026	0.000826	CcSEcCtD
Duloxetine—Body temperature increased—Etoposide—brain cancer	0.00026	0.000826	CcSEcCtD
Duloxetine—Rash—Temozolomide—brain cancer	0.00026	0.000824	CcSEcCtD
Duloxetine—Dermatitis—Temozolomide—brain cancer	0.000259	0.000823	CcSEcCtD
Duloxetine—Headache—Temozolomide—brain cancer	0.000258	0.000818	CcSEcCtD
Duloxetine—Nausea—Carmustine—brain cancer	0.000253	0.000803	CcSEcCtD
Duloxetine—Nausea—Temozolomide—brain cancer	0.000245	0.000776	CcSEcCtD
Duloxetine—Hypersensitivity—Etoposide—brain cancer	0.000243	0.00077	CcSEcCtD
Duloxetine—Asthenia—Etoposide—brain cancer	0.000236	0.00075	CcSEcCtD
Duloxetine—Pruritus—Etoposide—brain cancer	0.000233	0.00074	CcSEcCtD
Duloxetine—Diarrhoea—Etoposide—brain cancer	0.000225	0.000715	CcSEcCtD
Duloxetine—Dizziness—Etoposide—brain cancer	0.000218	0.000691	CcSEcCtD
Duloxetine—Vomiting—Etoposide—brain cancer	0.000209	0.000665	CcSEcCtD
Duloxetine—Rash—Etoposide—brain cancer	0.000208	0.000659	CcSEcCtD
Duloxetine—Dermatitis—Etoposide—brain cancer	0.000208	0.000658	CcSEcCtD
Duloxetine—Headache—Etoposide—brain cancer	0.000206	0.000655	CcSEcCtD
Duloxetine—Nausea—Etoposide—brain cancer	0.000196	0.000621	CcSEcCtD
Duloxetine—HTR2C—G alpha (q) signalling events—TRPC6—brain cancer	0.000166	0.00388	CbGpPWpGaD
Duloxetine—NPY1R—Signaling by GPCR—SHH—brain cancer	0.000164	0.00383	CbGpPWpGaD
Duloxetine—CYP2D6—Biological oxidations—CYP2C9—brain cancer	0.000164	0.00383	CbGpPWpGaD
Duloxetine—CYP2D6—Metapathway biotransformation—CYP2C9—brain cancer	0.000162	0.00377	CbGpPWpGaD
Duloxetine—NPY1R—Signaling by GPCR—TRPC6—brain cancer	0.000158	0.00369	CbGpPWpGaD
Duloxetine—NPY1R—Signaling by GPCR—PTCH1—brain cancer	0.000156	0.00363	CbGpPWpGaD
Duloxetine—NPY1R—Signaling by GPCR—SMO—brain cancer	0.000156	0.00363	CbGpPWpGaD
Duloxetine—SLC6A3—Transmembrane transport of small molecules—S100A10—brain cancer	0.000154	0.0036	CbGpPWpGaD
Duloxetine—SLC6A4—Circadian rythm related genes—SIRT1—brain cancer	0.000151	0.00353	CbGpPWpGaD
Duloxetine—HTR2C—Gastrin-CREB signalling pathway via PKC and MAPK—TRPC6—brain cancer	0.000149	0.00347	CbGpPWpGaD
Duloxetine—HTR2C—GPCR downstream signaling—OR14C36—brain cancer	0.000148	0.00345	CbGpPWpGaD
Duloxetine—HTR2C—GPCR downstream signaling—OR4C12—brain cancer	0.000148	0.00345	CbGpPWpGaD
Duloxetine—NPY1R—Signaling Pathways—ABR—brain cancer	0.000148	0.00345	CbGpPWpGaD
Duloxetine—HTR2A—GPCR ligand binding—PTCH2—brain cancer	0.000147	0.00342	CbGpPWpGaD
Duloxetine—HTR2A—G alpha (q) signalling events—TRPC6—brain cancer	0.000144	0.00337	CbGpPWpGaD
Duloxetine—CYP1A2—Aryl Hydrocarbon Receptor Pathway—HES1—brain cancer	0.000143	0.00334	CbGpPWpGaD
Duloxetine—NPY1R—Signaling Pathways—GLI2—brain cancer	0.000143	0.00333	CbGpPWpGaD
Duloxetine—CYP1A2—Biological oxidations—CYP2C9—brain cancer	0.000139	0.00324	CbGpPWpGaD
Duloxetine—HTR2A—SIDS Susceptibility Pathways—ESR2—brain cancer	0.000138	0.00323	CbGpPWpGaD
Duloxetine—CYP1A2—Metapathway biotransformation—CYP2C9—brain cancer	0.000137	0.0032	CbGpPWpGaD
Duloxetine—HTR2C—Signaling by GPCR—OR4C12—brain cancer	0.000134	0.00313	CbGpPWpGaD
Duloxetine—HTR2C—Signaling by GPCR—OR14C36—brain cancer	0.000134	0.00313	CbGpPWpGaD
Duloxetine—NPY1R—Signaling Pathways—GLI1—brain cancer	0.000134	0.00313	CbGpPWpGaD
Duloxetine—NPY1R—GPCR downstream signaling—VAV1—brain cancer	0.000131	0.00305	CbGpPWpGaD
Duloxetine—HTR2A—Gastrin-CREB signalling pathway via PKC and MAPK—TRPC6—brain cancer	0.000129	0.00301	CbGpPWpGaD
Duloxetine—HTR2A—GPCR downstream signaling—OR4C12—brain cancer	0.000129	0.003	CbGpPWpGaD
Duloxetine—HTR2A—GPCR downstream signaling—OR14C36—brain cancer	0.000129	0.003	CbGpPWpGaD
Duloxetine—NPY1R—Signaling Pathways—SUFU—brain cancer	0.000127	0.00297	CbGpPWpGaD
Duloxetine—NPY1R—Signaling Pathways—GFAP—brain cancer	0.000123	0.00286	CbGpPWpGaD
Duloxetine—NPY1R—Signaling by GPCR—VAV1—brain cancer	0.000119	0.00277	CbGpPWpGaD
Duloxetine—HTR6—GPCR ligand binding—SHH—brain cancer	0.000118	0.00275	CbGpPWpGaD
Duloxetine—HTR6—Signaling by GPCR—PTCH2—brain cancer	0.000118	0.00274	CbGpPWpGaD
Duloxetine—HTR2A—Signaling by GPCR—OR4C12—brain cancer	0.000117	0.00272	CbGpPWpGaD
Duloxetine—HTR2A—Signaling by GPCR—OR14C36—brain cancer	0.000117	0.00272	CbGpPWpGaD
Duloxetine—NPY1R—Signaling Pathways—HEY1—brain cancer	0.000116	0.00271	CbGpPWpGaD
Duloxetine—SLC6A4—Circadian rythm related genes—CDK4—brain cancer	0.000114	0.00267	CbGpPWpGaD
Duloxetine—NPY1R—Signaling Pathways—DLL1—brain cancer	0.000114	0.00266	CbGpPWpGaD
Duloxetine—HTR6—GPCR ligand binding—PTCH1—brain cancer	0.000112	0.00261	CbGpPWpGaD
Duloxetine—HTR6—GPCR ligand binding—SMO—brain cancer	0.000112	0.00261	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—OR4C12—brain cancer	0.000108	0.00251	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—OR14C36—brain cancer	0.000108	0.00251	CbGpPWpGaD
Duloxetine—HTR2A—SIDS Susceptibility Pathways—HES1—brain cancer	0.000108	0.00251	CbGpPWpGaD
Duloxetine—HTR6—GPCR downstream signaling—ABR—brain cancer	0.000102	0.00237	CbGpPWpGaD
Duloxetine—NPY1R—Signaling Pathways—SHH—brain cancer	9.7e-05	0.00226	CbGpPWpGaD
Duloxetine—NPY1R—Signaling Pathways—TRPC6—brain cancer	9.35e-05	0.00218	CbGpPWpGaD
Duloxetine—HTR6—Signaling by GPCR—ABR—brain cancer	9.23e-05	0.00215	CbGpPWpGaD
Duloxetine—NPY1R—Signaling Pathways—SMO—brain cancer	9.2e-05	0.00214	CbGpPWpGaD
Duloxetine—NPY1R—Signaling Pathways—PTCH1—brain cancer	9.2e-05	0.00214	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—DTX2—brain cancer	9.17e-05	0.00214	CbGpPWpGaD
Duloxetine—SLC6A4—SIDS Susceptibility Pathways—CTNNB1—brain cancer	8.96e-05	0.00209	CbGpPWpGaD
Duloxetine—HTR2C—GPCR ligand binding—SHH—brain cancer	8.69e-05	0.00203	CbGpPWpGaD
Duloxetine—HTR2C—Signaling by GPCR—PTCH2—brain cancer	8.66e-05	0.00202	CbGpPWpGaD
Duloxetine—NPY1R—GPCR downstream signaling—PIK3CG—brain cancer	8.3e-05	0.00193	CbGpPWpGaD
Duloxetine—CYP1A2—Aryl Hydrocarbon Receptor—RELA—brain cancer	8.27e-05	0.00193	CbGpPWpGaD
Duloxetine—HTR2C—GPCR ligand binding—SMO—brain cancer	8.24e-05	0.00192	CbGpPWpGaD
Duloxetine—HTR2C—GPCR ligand binding—PTCH1—brain cancer	8.24e-05	0.00192	CbGpPWpGaD
Duloxetine—SLC6A2—Transmembrane transport of small molecules—TRPC6—brain cancer	8.05e-05	0.00188	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—OR14C36—brain cancer	7.94e-05	0.00185	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—OR4C12—brain cancer	7.94e-05	0.00185	CbGpPWpGaD
Duloxetine—SLC6A4—SIDS Susceptibility Pathways—VEGFA—brain cancer	7.89e-05	0.00184	CbGpPWpGaD
Duloxetine—HTR2A—GPCR ligand binding—SHH—brain cancer	7.55e-05	0.00176	CbGpPWpGaD
Duloxetine—NPY1R—Signaling by GPCR—PIK3CG—brain cancer	7.53e-05	0.00176	CbGpPWpGaD
Duloxetine—HTR2A—Signaling by GPCR—PTCH2—brain cancer	7.52e-05	0.00175	CbGpPWpGaD
Duloxetine—HTR2C—GPCR downstream signaling—ABR—brain cancer	7.48e-05	0.00174	CbGpPWpGaD
Duloxetine—CYP1A2—Aryl Hydrocarbon Receptor Pathway—IL2—brain cancer	7.45e-05	0.00174	CbGpPWpGaD
Duloxetine—NPY1R—Signaling Pathways—NOTCH2—brain cancer	7.35e-05	0.00171	CbGpPWpGaD
Duloxetine—HTR2A—GPCR ligand binding—SMO—brain cancer	7.16e-05	0.00167	CbGpPWpGaD
Duloxetine—HTR2A—GPCR ligand binding—PTCH1—brain cancer	7.16e-05	0.00167	CbGpPWpGaD
Duloxetine—SLC6A3—Transmembrane transport of small molecules—TRPC6—brain cancer	7.13e-05	0.00166	CbGpPWpGaD
Duloxetine—NPY1R—Signaling Pathways—VAV1—brain cancer	7.01e-05	0.00163	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—PTCH2—brain cancer	6.95e-05	0.00162	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—OR4C12—brain cancer	6.89e-05	0.00161	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—OR14C36—brain cancer	6.89e-05	0.00161	CbGpPWpGaD
Duloxetine—HTR2C—Signaling by GPCR—ABR—brain cancer	6.8e-05	0.00158	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—DTX2—brain cancer	6.75e-05	0.00157	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—HES5—brain cancer	6.73e-05	0.00157	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—STRADA—brain cancer	6.53e-05	0.00152	CbGpPWpGaD
Duloxetine—HTR2A—GPCR downstream signaling—ABR—brain cancer	6.5e-05	0.00152	CbGpPWpGaD
Duloxetine—HTR6—GPCR downstream signaling—TRPC6—brain cancer	6.43e-05	0.0015	CbGpPWpGaD
Duloxetine—CYP1A2—Aryl Hydrocarbon Receptor—VEGFA—brain cancer	6.33e-05	0.00148	CbGpPWpGaD
Duloxetine—HTR6—Signaling by GPCR—SHH—brain cancer	6.06e-05	0.00141	CbGpPWpGaD
Duloxetine—NPY1R—Signaling Pathways—HES1—brain cancer	6.03e-05	0.00141	CbGpPWpGaD
Duloxetine—HTR2A—Signaling by GPCR—ABR—brain cancer	5.9e-05	0.00138	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—DTX2—brain cancer	5.86e-05	0.00137	CbGpPWpGaD
Duloxetine—HTR6—Signaling by GPCR—TRPC6—brain cancer	5.84e-05	0.00136	CbGpPWpGaD
Duloxetine—NPY1R—GPCR downstream signaling—IL2—brain cancer	5.84e-05	0.00136	CbGpPWpGaD
Duloxetine—CYP1A2—Aryl Hydrocarbon Receptor—MYC—brain cancer	5.83e-05	0.00136	CbGpPWpGaD
Duloxetine—HTR6—Signaling by GPCR—SMO—brain cancer	5.74e-05	0.00134	CbGpPWpGaD
Duloxetine—HTR6—Signaling by GPCR—PTCH1—brain cancer	5.74e-05	0.00134	CbGpPWpGaD
Duloxetine—NPY1R—Signaling Pathways—PDGFRA—brain cancer	5.74e-05	0.00134	CbGpPWpGaD
Duloxetine—CYP1A2—Aryl Hydrocarbon Receptor—EGFR—brain cancer	5.7e-05	0.00133	CbGpPWpGaD
Duloxetine—CYP1A2—Aryl Hydrocarbon Receptor Pathway—EGFR—brain cancer	5.7e-05	0.00133	CbGpPWpGaD
Duloxetine—NPY1R—Signaling Pathways—SPP1—brain cancer	5.57e-05	0.0013	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—ABR—brain cancer	5.45e-05	0.00127	CbGpPWpGaD
Duloxetine—HTR2A—SIDS Susceptibility Pathways—CTNNB1—brain cancer	5.39e-05	0.00126	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism of lipids and lipoproteins—CYP2C9—brain cancer	5.34e-05	0.00125	CbGpPWpGaD
Duloxetine—NPY1R—Signaling by GPCR—IL2—brain cancer	5.3e-05	0.00124	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—GLI2—brain cancer	5.26e-05	0.00123	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—PTCH2—brain cancer	5.12e-05	0.00119	CbGpPWpGaD
Duloxetine—NPY1R—Signaling Pathways—IRS2—brain cancer	5.04e-05	0.00117	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—HES5—brain cancer	4.95e-05	0.00116	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—GLI1—brain cancer	4.95e-05	0.00115	CbGpPWpGaD
Duloxetine—SLC6A4—Circadian rythm related genes—TP53—brain cancer	4.87e-05	0.00113	CbGpPWpGaD
Duloxetine—HTR6—GPCR downstream signaling—VAV1—brain cancer	4.82e-05	0.00112	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—STRADA—brain cancer	4.81e-05	0.00112	CbGpPWpGaD
Duloxetine—HTR2A—SIDS Susceptibility Pathways—VEGFA—brain cancer	4.75e-05	0.00111	CbGpPWpGaD
Duloxetine—HTR2C—GPCR downstream signaling—TRPC6—brain cancer	4.74e-05	0.0011	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—SUFU—brain cancer	4.69e-05	0.00109	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—GFAP—brain cancer	4.53e-05	0.00106	CbGpPWpGaD
Duloxetine—HTR2C—Signaling by GPCR—SHH—brain cancer	4.46e-05	0.00104	CbGpPWpGaD
Duloxetine—NPY1R—Signaling Pathways—PIK3CG—brain cancer	4.45e-05	0.00104	CbGpPWpGaD
Duloxetine—NPY1R—Signaling Pathways—APC—brain cancer	4.45e-05	0.00104	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—PTCH2—brain cancer	4.44e-05	0.00104	CbGpPWpGaD
Duloxetine—HTR6—Signaling by GPCR—VAV1—brain cancer	4.38e-05	0.00102	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—HES5—brain cancer	4.3e-05	0.001	CbGpPWpGaD
Duloxetine—HTR2C—Signaling by GPCR—TRPC6—brain cancer	4.3e-05	0.001	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—HEY1—brain cancer	4.29e-05	0.001	CbGpPWpGaD
Duloxetine—HTR2C—Signaling by GPCR—PTCH1—brain cancer	4.23e-05	0.000986	CbGpPWpGaD
Duloxetine—HTR2C—Signaling by GPCR—SMO—brain cancer	4.23e-05	0.000986	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—DLL1—brain cancer	4.21e-05	0.000981	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—STRADA—brain cancer	4.18e-05	0.000974	CbGpPWpGaD
Duloxetine—HTR2A—GPCR downstream signaling—TRPC6—brain cancer	4.11e-05	0.000959	CbGpPWpGaD
Duloxetine—NPY1R—Signaling by GPCR—EGFR—brain cancer	4.05e-05	0.000945	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—ABR—brain cancer	4.01e-05	0.000936	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism of lipids and lipoproteins—IDH1—brain cancer	3.9e-05	0.00091	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—GLI2—brain cancer	3.88e-05	0.000904	CbGpPWpGaD
Duloxetine—HTR2A—Signaling by GPCR—SHH—brain cancer	3.87e-05	0.000903	CbGpPWpGaD
Duloxetine—HTR2C—Gastrin-CREB signalling pathway via PKC and MAPK—EGFR—brain cancer	3.81e-05	0.000887	CbGpPWpGaD
Duloxetine—HTR2A—Signaling by GPCR—TRPC6—brain cancer	3.74e-05	0.000871	CbGpPWpGaD
Duloxetine—HTR2A—Signaling by GPCR—SMO—brain cancer	3.67e-05	0.000856	CbGpPWpGaD
Duloxetine—HTR2A—Signaling by GPCR—PTCH1—brain cancer	3.67e-05	0.000856	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—GLI1—brain cancer	3.65e-05	0.00085	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—SHH—brain cancer	3.58e-05	0.000834	CbGpPWpGaD
Duloxetine—HTR2C—GPCR downstream signaling—VAV1—brain cancer	3.55e-05	0.000828	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—ABR—brain cancer	3.49e-05	0.000813	CbGpPWpGaD
Duloxetine—NPY1R—Signaling Pathways—RELA—brain cancer	3.48e-05	0.000811	CbGpPWpGaD
Duloxetine—NPY1R—Signaling Pathways—ERBB2—brain cancer	3.46e-05	0.000806	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—SUFU—brain cancer	3.46e-05	0.000806	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—TRPC6—brain cancer	3.45e-05	0.000805	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—PTCH1—brain cancer	3.39e-05	0.000791	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—SMO—brain cancer	3.39e-05	0.000791	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—GLI2—brain cancer	3.37e-05	0.000785	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—GFAP—brain cancer	3.33e-05	0.000777	CbGpPWpGaD
Duloxetine—HTR2A—Gastrin-CREB signalling pathway via PKC and MAPK—EGFR—brain cancer	3.31e-05	0.000771	CbGpPWpGaD
Duloxetine—HTR2C—Signaling by GPCR—VAV1—brain cancer	3.22e-05	0.000751	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—GLI1—brain cancer	3.17e-05	0.000738	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—HEY1—brain cancer	3.16e-05	0.000737	CbGpPWpGaD
Duloxetine—NPY1R—Signaling Pathways—IL2—brain cancer	3.13e-05	0.00073	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—DLL1—brain cancer	3.1e-05	0.000723	CbGpPWpGaD
Duloxetine—HTR2A—GPCR downstream signaling—VAV1—brain cancer	3.08e-05	0.000719	CbGpPWpGaD
Duloxetine—HTR6—GPCR downstream signaling—PIK3CG—brain cancer	3.06e-05	0.000714	CbGpPWpGaD
Duloxetine—NPY1R—Signaling Pathways—CCND1—brain cancer	3.05e-05	0.000712	CbGpPWpGaD
Duloxetine—NPY1R—Signaling Pathways—CTNNB1—brain cancer	3.02e-05	0.000705	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—SUFU—brain cancer	3e-05	0.0007	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—GFAP—brain cancer	2.9e-05	0.000675	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—CYP2C9—brain cancer	2.81e-05	0.000655	CbGpPWpGaD
Duloxetine—HTR2A—Signaling by GPCR—VAV1—brain cancer	2.8e-05	0.000653	CbGpPWpGaD
Duloxetine—HTR6—Signaling by GPCR—PIK3CG—brain cancer	2.78e-05	0.000648	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—HEY1—brain cancer	2.74e-05	0.00064	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—NOTCH2—brain cancer	2.71e-05	0.000632	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—DLL1—brain cancer	2.69e-05	0.000628	CbGpPWpGaD
Duloxetine—NPY1R—Signaling Pathways—VEGFA—brain cancer	2.66e-05	0.000621	CbGpPWpGaD
Duloxetine—NPY1R—Signaling Pathways—STAT3—brain cancer	2.64e-05	0.000614	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—SHH—brain cancer	2.64e-05	0.000614	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—VAV1—brain cancer	2.59e-05	0.000603	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—TRPC6—brain cancer	2.54e-05	0.000592	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—PTCH1—brain cancer	2.5e-05	0.000582	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—SMO—brain cancer	2.5e-05	0.000582	CbGpPWpGaD
Duloxetine—NPY1R—Signaling Pathways—MYC—brain cancer	2.45e-05	0.000571	CbGpPWpGaD
Duloxetine—NPY1R—Signaling Pathways—EGFR—brain cancer	2.4e-05	0.000558	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—BSG—brain cancer	2.39e-05	0.000557	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—CYP2C9—brain cancer	2.38e-05	0.000554	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—SHH—brain cancer	2.29e-05	0.000534	CbGpPWpGaD
Duloxetine—HTR2C—GPCR downstream signaling—PIK3CG—brain cancer	2.25e-05	0.000525	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—HES1—brain cancer	2.22e-05	0.000518	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—TRPC6—brain cancer	2.21e-05	0.000515	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—SMO—brain cancer	2.17e-05	0.000506	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—PTCH1—brain cancer	2.17e-05	0.000506	CbGpPWpGaD
Duloxetine—HTR6—GPCR downstream signaling—IL2—brain cancer	2.15e-05	0.000502	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—PDGFRA—brain cancer	2.12e-05	0.000494	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—SPP1—brain cancer	2.06e-05	0.000479	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—IDH1—brain cancer	2.05e-05	0.000479	CbGpPWpGaD
Duloxetine—HTR2C—Signaling by GPCR—PIK3CG—brain cancer	2.05e-05	0.000477	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—BSG—brain cancer	2.02e-05	0.000471	CbGpPWpGaD
Duloxetine—NPY1R—Signaling Pathways—TP53—brain cancer	2.01e-05	0.000469	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—NOTCH2—brain cancer	2e-05	0.000466	CbGpPWpGaD
Duloxetine—HTR2A—GPCR downstream signaling—PIK3CG—brain cancer	1.96e-05	0.000456	CbGpPWpGaD
Duloxetine—HTR6—Signaling by GPCR—IL2—brain cancer	1.96e-05	0.000456	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—VAV1—brain cancer	1.9e-05	0.000444	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—IRS2—brain cancer	1.86e-05	0.000433	CbGpPWpGaD
Duloxetine—HTR2A—Signaling by GPCR—PIK3CG—brain cancer	1.78e-05	0.000414	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—IDH1—brain cancer	1.74e-05	0.000405	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—NOTCH2—brain cancer	1.73e-05	0.000404	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—VAV1—brain cancer	1.65e-05	0.000385	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—PIK3CG—brain cancer	1.64e-05	0.000383	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—APC—brain cancer	1.64e-05	0.000383	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—HES1—brain cancer	1.64e-05	0.000382	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—ENO2—brain cancer	1.62e-05	0.000378	CbGpPWpGaD
Duloxetine—HTR2C—GPCR downstream signaling—IL2—brain cancer	1.59e-05	0.00037	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—PDGFRA—brain cancer	1.56e-05	0.000364	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—SPP1—brain cancer	1.51e-05	0.000353	CbGpPWpGaD
Duloxetine—HTR6—Signaling by GPCR—EGFR—brain cancer	1.5e-05	0.000349	CbGpPWpGaD
Duloxetine—HTR2C—Signaling by GPCR—IL2—brain cancer	1.44e-05	0.000336	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—HES1—brain cancer	1.42e-05	0.000332	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CG—brain cancer	1.42e-05	0.00033	CbGpPWpGaD
Duloxetine—HTR2A—GPCR downstream signaling—IL2—brain cancer	1.38e-05	0.000321	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—ENO2—brain cancer	1.37e-05	0.00032	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—IRS2—brain cancer	1.37e-05	0.000319	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—PDGFRA—brain cancer	1.35e-05	0.000316	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—SPP1—brain cancer	1.31e-05	0.000306	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—RELA—brain cancer	1.28e-05	0.000299	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—ERBB2—brain cancer	1.27e-05	0.000297	CbGpPWpGaD
Duloxetine—HTR2A—Signaling by GPCR—IL2—brain cancer	1.25e-05	0.000292	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—APC—brain cancer	1.21e-05	0.000282	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—PIK3CG—brain cancer	1.21e-05	0.000282	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—IRS2—brain cancer	1.19e-05	0.000277	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—IL2—brain cancer	1.16e-05	0.000269	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—CCND1—brain cancer	1.13e-05	0.000263	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—CTNNB1—brain cancer	1.12e-05	0.00026	CbGpPWpGaD
Duloxetine—HTR2C—Signaling by GPCR—EGFR—brain cancer	1.1e-05	0.000257	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—PIK3CG—brain cancer	1.05e-05	0.000245	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—APC—brain cancer	1.05e-05	0.000245	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—VEGFA—brain cancer	9.82e-06	0.000229	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—STAT3—brain cancer	9.72e-06	0.000227	CbGpPWpGaD
Duloxetine—HTR2A—Signaling by GPCR—EGFR—brain cancer	9.56e-06	0.000223	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—RELA—brain cancer	9.45e-06	0.00022	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—ERBB2—brain cancer	9.39e-06	0.000219	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—MYC—brain cancer	9.03e-06	0.000211	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—EGFR—brain cancer	8.84e-06	0.000206	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—IL2—brain cancer	8.51e-06	0.000198	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—CCND1—brain cancer	8.29e-06	0.000193	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—CTNNB1—brain cancer	8.21e-06	0.000191	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—RELA—brain cancer	8.2e-06	0.000191	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—ERBB2—brain cancer	8.15e-06	0.00019	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—PIK3CG—brain cancer	7.44e-06	0.000174	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—TP53—brain cancer	7.42e-06	0.000173	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—IL2—brain cancer	7.39e-06	0.000172	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—VEGFA—brain cancer	7.23e-06	0.000169	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—CCND1—brain cancer	7.2e-06	0.000168	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—STAT3—brain cancer	7.16e-06	0.000167	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—CTNNB1—brain cancer	7.13e-06	0.000166	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—MYC—brain cancer	6.65e-06	0.000155	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—EGFR—brain cancer	6.51e-06	0.000152	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—PIK3CG—brain cancer	6.31e-06	0.000147	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—VEGFA—brain cancer	6.28e-06	0.000146	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—STAT3—brain cancer	6.22e-06	0.000145	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—MYC—brain cancer	5.78e-06	0.000135	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—EGFR—brain cancer	5.65e-06	0.000132	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—TP53—brain cancer	5.46e-06	0.000127	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—TP53—brain cancer	4.74e-06	0.000111	CbGpPWpGaD
